Please login to the form below
phentermine
This page shows the latest phentermine news and features for those working in and with pharma, biotech and healthcare.
Novo Nordisk taps Noom for digital help with its push into obesity
developers. There is a handful of approved drug therapies – including GlaxoSmithKline’s/Roche’s lipase inhibitor, Xenical (orlistat), Eisai’s Belviq (lorcaserin) and Vivus Qsymia (phentermine/topiramate) – but none have been
Latest news
-
Takeda files block on generic diet pill launch
But despite being third to market among the new generation of obesity therapies after Eisai and Arena's Belviq (lorcaserin) and Vivus' Qsymia (phentermine/topiramate), both approved 18 months ago, Orexigen
-
FDA panel backs Sprout Pharma's 'female Viagra'
REMS are already in place for other 'lifestyle' drugs such as Vivus' Qsymia (phentermine/topiramate) for obesity and Pfizer's smoking cessation therapy Chantix (varenicline).
-
Saxenda debuts in US with $1,000-a-month price tag
s Contrave (bupropion/naltrexone), Arena/Eisai's Belviq (lorcaserin) and Vivus' Qsymia (phentermine/topiramate), although for patients the monthly cost will fall depending on their insurance cover. .
-
Positive data in Saxenda diabetes prevention study
the US of three other drugs; Eisai and Arena's Belviq (lorcaserin), Vivus' Qsymia (phentermine/topiramate) and Orexigen's Contrave (naltrexone and bupropion).
-
CHMP thumbs up for Novo's obesity drug Saxenda
new products - Eisai and Arena's Belviq (lorcaserin), Vivus' Qsymia (phentermine/topiramate) and Orexigen's Contrave (naltrexone and bupropion) in the last couple of years in the US and other world
Takeda files block on generic diet pill launch
FDA panel backs Sprout Pharma's 'female Viagra'
Saxenda debuts in US with $1,000-a-month price tag
More from news
Approximately 2 fully matching, plus 27 partially matching documents found.
Latest appointments
-
Anthony Zook resigns as Vivus CEO
shareholders became unhappy with the way Vivus handled the launch of its obesity drug Qsymia (phentermine/ topiramat).
Anthony Zook resigns as Vivus CEO
More from appointments
Approximately 1 fully matching, plus 0 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Account Manager / Senior Account Manager - Creative MedComms - C...
-
Excellent Remuneration
- Account Manager - Creative Healthcare Communications - South Wes...
-
Excellent Remuneration
-
Account Management
-
Competitive Salary Offered
-
Publications Director
-
Competitive Salary
- Senior Account / Programme Manager - MedComms - Buckinghamshire
-
Highly Competitive Remuneration packages
- Group Account Director, Healthcare Advertising/ Brand comms, Lon...
-
8 month contract up to £90K
-
Account Manager
-
Competitive Salary
-
Medical Editor
-
Competitive Salary
-
Senior Account Executive
-
Competitive Salary
- Senior Account Manager/ Account Director
-
Competitive Salary Offered
- Head of Strategic Planning, Healthcare Advertising/ Brand comms,...
-
Six figure salary
- Senior Medical Writer– Medical Education – Oxford - London
-
Excellent Remuneration Package
- Medical Writers (All levels) Editorial / Scientific Leads & ...
-
Highly Competitive Remuneration packages
-
Associate Account Director
-
Competitive Salary
-
Senior Medical Writer
-
Competitive Salary
- Senior & Principal Medical Writer
-
Competitive Salary Offered
- Novavax announces further delays for regulatory filings of COVID-19 vaccine
- Merck & Co reveals plans for women’s health spinoff Organon
- Positive results for GSK/CureVac’s COVID-19 vaccine
- EMA launches rolling review of GSK/Vir Biotech’s mAb for early COVID-19
- Biogen and Capsigen to collaborate on gene therapies
- CanSinoBIO considers booster jab for COVID-19 vaccine
- Research Partnership’s MedTech Division appoints two Directors
- VMLY&Rx launches new payer agency in the US
- Biogen and Envisagenics to advance RNA splicing research for CNS diseases
- Positive results for GSK/CureVac’s COVID-19 vaccine
- New trial data for Keytruda in triple-negative breast cancer
- NICE recommends Keytruda for colorectal cancer patients with rare mutations
- Merck & Co reveals plans for women’s health spinoff Organon
- UK launches subscription-style payment pilot to incentivise pharma antibiotics R&D
- Why female mentorship is so powerful in pharma
- Positive results for GSK/CureVac’s COVID-19 vaccine
- Avoiding A Series of Unfortunate Events: launch lessons from lockdown
- Can protein degraders unlock ‘undruggable’ drug targets?
PMHub
Spirit
We find the soul in the science, the humanity in the data, harnessing the power of creativity to deliver medical...
Latest intelligence
- How innovating study sites can improve patient recruitment efficiency
- There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
- Avoiding A Series of Unfortunate Events: launch lessons from lockdown
- Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
- 6 reasons patients drop out of clinical trials and 6 ways to fix it
- If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....
